PHILADELPHIA – A Penn professor’s research efforts to fight debilitating degenerative muscle diseases have earned him international recognition by the Deputy Ruler of Dubai and Minister of Finance and Industry of the United Arab Emirates.
H. Lee Sweeney, PhD
Click on thumbnail
to view full-size image
In November 2008 Sheikh Hamdan Bin Rashid Al Maktoum named H. Lee Sweeney, PhD, William Maul Measey Professor at the University of Pennsylvania School of Medicine, as one of three recipients of the Hamdan Award for Medical Research Excellence. The award honors individuals whose medical research has helped to improve the lives of thousands of people worldwide.
Dr. Sweeney, the sole US recipient of this year’s award, was recognized for his research on muscular dystrophy, with emphasis on the impact in the area of pharmacogenomics, the science of how genetic variations influence individual differences in responses to drugs.
“This award recognizes a number of contributions I have made in the area of combating muscle weakness and muscular dystrophy, including my recent role in the development of a drug which may be able to treat a subset of patients with muscular dystrophy and other genetic disorders,” Sweeney says. “It was a great honor and surprise to have my work recognized while the clinical development of [such drugs] is ongoing.”
For much of his career, Dr. Sweeney has studied the mechanisms that help control muscle function with the hope of gaining a better understanding of ways to thwart muscle deterioration caused by age and degenerative diseases and promote muscle growth.
Dr. Sweeney’s research includes the study of animal models of Duchenne’s muscular dystrophy (DMD), a rapid muscle degenerative disease that can lead to paralysis of all muscles in the body, including the heart and diaphragm, and death. His research team at Penn uses gene therapy, a method where new genes are inserted into cells, to help treat genetic diseases as a means to validate possible therapeutic targets.
Beginning in 1999, Dr. Sweeney’s lab published the first paper showing that a family of antibiotics known as aminoglycosides could be used to suppress disease-causing genes in DMD mice. In 2007, Dr. Sweeney then led a team of researchers who showed a new drug called PTC124 could override a genetic mutation causing muscle degeneration in DMD mice without causing side effects. PTC124, developed by PTC Therapeutics in collaboration with Dr. Sweeney’s lab, is currently in the pivotal clinical trial phase in DMD patients.
As part of the Hamdan Award for Medical Research Excellence Dr. Sweeney was invited to present a lecture at the 5th Dubai International Conference for Medical Sciences last December, where he discussed his most recent studies.
PENN Medicine is a $3.6 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.
Penn's School of Medicine is currently ranked #4 in the nation in U.S.News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,700 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System (UPHS) includes its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s top ten “Honor Roll” hospitals by U.S.News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center. In addition UPHS includes a primary-care provider network; a faculty practice plan; home care, hospice, and nursing home; three multispecialty satellite facilities; as well as the Penn Medicine Rittenhouse campus, which offers comprehensive inpatient rehabilitation facilities and outpatient services in multiple specialties.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.